Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Non-Current Assets: 2023-2025

Historic Non-Current Assets for Zenas BioPharma (ZBIO) over the last 1 years, with Sep 2025 value amounting to $25.4 million.

  • Zenas BioPharma's Non-Current Assets rose 162.85% to $25.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.4 million, marking a year-over-year increase of 162.85%. This contributed to the annual value of $14.0 million for FY2024, which is 67.68% up from last year.
  • Zenas BioPharma's Non-Current Assets amounted to $25.4 million in Q3 2025, which was up 75.22% from $14.5 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Non-Current Assets registered a high of $25.4 million during Q3 2025, and its lowest value of $8.4 million during Q4 2023.
  • Its 3-year average for Non-Current Assets is $14.6 million, with a median of $14.3 million in 2024.
  • Data for Zenas BioPharma's Non-Current Assets shows a peak YoY skyrocketed of 162.85% (in 2025) over the last 5 years.
  • Quarterly analysis of 3 years shows Zenas BioPharma's Non-Current Assets stood at $8.4 million in 2023, then surged by 67.68% to $14.0 million in 2024, then surged by 162.85% to $25.4 million in 2025.
  • Its Non-Current Assets stands at $25.4 million for Q3 2025, versus $14.5 million for Q2 2025 and $16.0 million for Q1 2025.